TY - JOUR
T1 - Applying genetic approaches to the treatment of nicotine dependence
AU - Lerman, Caryn
AU - Niaura, Raymond
N1 - Funding Information:
The authors would like to thank Freda Patterson, M.A. and Maryanne Foster for their assistance in the preparation of this manuscript. Supported by grants from the National Cancer Institute (P50 CA84718), RO1 CA63562 (C Lerman), and P50CA084719 (R Niaura), and the National Heart Lung and Blood Institute RO1 HL32318 (R Niaura).
PY - 2002
Y1 - 2002
N2 - To advance the science of tobacco control, an enhanced understanding of the bio-behavioral basis of nicotine addiction is needed. In this study, we provide an overview of data from investigations of genetic factors in smoking behavior, discuss potential bio-behavioral mechanisms and effect modifiers, and suggest avenues for pharmacogenetics research in the area of smoking cessation treatment. The evidence to date is very consistent with respect to the significance of genetic contributions to smoking behavior. However, attempts to elucidate the role of specific genetic variants have met with mixed success. Explanations for the lack of consistency in the results of genetic association studies include biases in ascertainment, ethnic admixture, lack of attention to covariates or modifiers of genetic risk, and the need for more refined phenotypes. As the field of genetics and smoking research progresses, increasing attention is being devoted to gene-environment interactions, with particular attention to the identification of genetic variants that may modify the effects of pharmacological treatment for smoking. With advances in molecular biology and genomics technology, individualized tailoring of smoking cessation therapy to genotype is within our grasp. Such research has the potential to improve treatment outcome, thereby reducing morbidity and mortality from smoking-related disease.
AB - To advance the science of tobacco control, an enhanced understanding of the bio-behavioral basis of nicotine addiction is needed. In this study, we provide an overview of data from investigations of genetic factors in smoking behavior, discuss potential bio-behavioral mechanisms and effect modifiers, and suggest avenues for pharmacogenetics research in the area of smoking cessation treatment. The evidence to date is very consistent with respect to the significance of genetic contributions to smoking behavior. However, attempts to elucidate the role of specific genetic variants have met with mixed success. Explanations for the lack of consistency in the results of genetic association studies include biases in ascertainment, ethnic admixture, lack of attention to covariates or modifiers of genetic risk, and the need for more refined phenotypes. As the field of genetics and smoking research progresses, increasing attention is being devoted to gene-environment interactions, with particular attention to the identification of genetic variants that may modify the effects of pharmacological treatment for smoking. With advances in molecular biology and genomics technology, individualized tailoring of smoking cessation therapy to genotype is within our grasp. Such research has the potential to improve treatment outcome, thereby reducing morbidity and mortality from smoking-related disease.
KW - Genetics
KW - Nicotine
KW - Smoking
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=0037152634&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037152634&partnerID=8YFLogxK
U2 - 10.1038/sj.onc.1205801
DO - 10.1038/sj.onc.1205801
M3 - Article
C2 - 12379882
AN - SCOPUS:0037152634
SN - 0950-9232
VL - 21-48
SP - 7412
EP - 7420
JO - Oncogene
JF - Oncogene
IS - 6
ER -